Some exciting news for Liver Transplant patients about a new study just about to start.

The MELODY Study aims to assess antibody responses following three Covid-19 vaccine doses in immunocompromised people.  It will include people who have received solid organ transplants, people with rare autoimmune diseases receiving immunosuppression and people who had a diagnosis of blood cancer.  It aims to recruit 12,000 solid organ transplant patients.

It will assess:

  • How many immunocompromised people have detectable antibodies against COVID-19 following three vaccines. Antibodies will be tested using a finger prick testing kit sent to their home.
  • Investigate whether lack of detectable antibodies are associated with risk of infection over a six month period
  • Investigate what factors are associated with lack of detectable antibodies in immunocompromised people eg the type of immunosuppressant medication taken. This will be determined by asking participants to complete an online questionnaire when reporting their antibody results from the test.

If you are interested in participating in the study, please go to:

Survey (melodystudy.org)